Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And Potential To Reduce Opioid Use
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics announced that its product ZYNRELEF has been included in the proposed 2025 non-opioid policy for pain relief under Medicare OPPS and ASC payment systems. This policy is set to be effective from April 1, 2025, and is based on ZYNRELEF's postoperative pain indication and its potential to reduce opioid use.
July 15, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Heron Therapeutics' ZYNRELEF has been included in the proposed 2025 non-opioid policy for pain relief under Medicare OPPS and ASC payment systems, effective April 1, 2025. This inclusion is based on ZYNRELEF's postoperative pain indication and its potential to reduce opioid use.
The inclusion of ZYNRELEF in the proposed 2025 non-opioid policy under Medicare OPPS and ASC payment systems is a significant regulatory milestone for Heron Therapeutics. This could potentially increase the adoption of ZYNRELEF, reduce opioid use, and positively impact HRTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100